CALC
NASDAQCalciMedica Inc.
Price$2.05-3.10 (-60.19%)
2026-06-052026-09-09
News · 26 weeks49+129%
2026-03-152026-09-06
Mix3890d
- Insider17(45%)
- SEC Filings11(29%)
- Other8(21%)
- Offering1(3%)
- Analyst1(3%)
Latest news
25 items- PRCalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceLA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will present and participate in 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026. About CalciMedicaCalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunolog
- SECSEC Form 8-K filed by CalciMedica Inc.8-K - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form 8-K filed by CalciMedica Inc.8-K - CalciMedica, Inc. (0001534133) (Filer)
- PRCalciMedica Announces One-for-Five Reverse Stock SplitLA JOLLA, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-5, effective at 5:00 p.m. ET on August 28, 2026. CalciMedica’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on August 31, 2026 under CalciMedica’s existing trading symbol "CALC" with a new
- SECSEC Form SCHEDULE 13G filed by CalciMedica Inc.SCHEDULE 13G - CalciMedica, Inc. (0001534133) (Subject)
- INSIDERSEC Form 4 filed by Large owner Alafi Capital Co Llc4 - CalciMedica, Inc. (0001534133) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by CalciMedica Inc.SCHEDULE 13D/A - CalciMedica, Inc. (0001534133) (Subject)
- INSIDERSEC Form 4 filed by Director Shaw Allan4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Director Glicklich Alan4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Director Guerard Frederic4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Director Zaytsev Evgeny4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Director Wilson Robert N4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Hebbar Sudarshan4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF BUSINESS OFFICER Roberts Eric W4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF EXECUTIVE OFFICER Leheny A. Rachel4 - CalciMedica, Inc. (0001534133) (Issuer)
- ANALYSTGuggenheim initiated coverage on CalciMedica with a new price targetGuggenheim initiated coverage of CalciMedica with a rating of Buy and set a new price target of $9.00
- SECSEC Form 10-Q filed by CalciMedica Inc.10-Q - CalciMedica, Inc. (0001534133) (Filer)
- SECCalciMedica Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CalciMedica, Inc. (0001534133) (Filer)
- PRCalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesCompleted private placement financing of up to approximately $49 million to advance pulmonary hypertension program Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension (PAH) and CM5480 IND submission both anticipated in mid-2027 FDA aligned that the primary endpoint for the Phase 2b trial in acute pancreatitis will measure whether Auxora can reduce new-onset severe respiratory failure LA JOLLA, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic,
- SECSEC Form EFFECT filed by CalciMedica Inc.EFFECT - CalciMedica, Inc. (0001534133) (Filer)
- PRCalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational EndpointsFDA aligned on new-onset severe respiratory failure as the Phase 2b primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary endpointsFDA aligned on a strategy to evaluate elevated lactate dehydrogenase (LDH) as a potential enrichment marker for identifying patients at increased risk of new-onset severe respiratory failureLA JOLLA, Calif., July 29, 2026 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that, fo
- SECSEC Form S-3 filed by CalciMedica Inc.S-3 - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form DEF 14A filed by CalciMedica Inc.DEF 14A - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form PRE 14A filed by CalciMedica Inc.PRE 14A - CalciMedica, Inc. (0001534133) (Filer)
- INSIDERNew insider Alafi Capital Co Llc claimed ownership of 5,112,345 shares (SEC Form 3)3 - CalciMedica, Inc. (0001534133) (Issuer)
CALC FAQ
6 questionsWhere does CALC stock trade?
CalciMedica Inc. (CALC) is listed on NASDAQ.What sector and industry is CALC in?
CalciMedica Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did CalciMedica Inc. go public?
CalciMedica Inc. (CALC) completed its IPO in 2023.What are analysts saying about CALC?
CalciMedica Inc. has had 2 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $900.00 price target on 2026-08-20. Recent price targets cluster around $900.00.What companies are similar to CALC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CALC side-by-side with any of them on Quantisnow.How can I track CALC on Quantisnow?
Quantisnow aggregates CalciMedica Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CALC to receive live email and push alerts on every new disclosure.